Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.75 |
| ▸ | BRD2 | P25440 | 1/20 | 0.69 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.69 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.69 |
| ▸ | PDE5A | O76074 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24007718 | 1.00 | BRD4 (0.75) | BRD4BRD2BRD3BRDTPDE5A | |
| SCHEMBL21787970 | 0.92 | BRD4 (0.75) | BRD4BRD2BRD3BRDT | |
| SCHEMBL21787735 | 0.92 | BRD4 (0.75) | BRD4BRD2BRD3BRDT | |
| SCHEMBL21787868 | 0.90 | BRD4 (0.75) | BRD4BRD2BRD3BRDTPDE5A | |
| SCHEMBL24007720 | 0.90 | BRD4 (0.75) | BRD4BRD2BRD3BRDTPDE5A | |
| SCHEMBL24006894 | 0.90 | BRD4 (0.75) | BRD4BRD2BRD3BRDTPDE5A | |
| SCHEMBL21788062 | 0.88 | BRD4 (0.79) | BRD4BRD2BRD3BRDT | |
| SCHEMBL21787803 | 0.88 | BRD4 (0.79) | BRD4BRD2BRD3BRDT | |
| SCHEMBL21787732 | 0.86 | BRD4 (0.81) | BRD4BRD2BRD3BRDT | |
| SCHEMBL21787823 | 0.86 | BRD4 (0.81) | BRD4BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346336-A1 | FURAN DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-11-11 | — | — | US | disclosed |
| WO-2020043821-A1 | FURAN DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346336-A1 | FURAN DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | BRD4 1/4885BRD2 5/4885BRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.